Biogen Inc. logo

Biogen Inc. (BIIB)

Market Closed
30 May, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
129. 79
-2.96
-2.23%
$
18.43B Market Cap
24.69 P/E Ratio
0% Div Yield
3,640,000 Volume
14.99 Eps
$ 132.75
Previous Close
Day Range
129.62 132.59
Year Range
110.04 238
Earnings results expected in 59 days

Summary

BIIB closed yesterday lower at $129.79, a decrease of 2.23% from Thursday's close, completing a monthly increase of 7.83% or $9.42. Over the past 12 months, BIIB stock lost -15.63%.
BIIB pays dividends to its shareholders, with the most recent payment made on Feb 01, 2017.
The last earnings report, released on Apr 22, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -1.24%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
Biogen Inc. has completed 2 stock splits, with the recent split occurring on Jan 18, 2001.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track BIIB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

BIIB Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise Collaboration leverages City Therapeutics' next-generation RNAi engineering technologies and Biogen's extensive drug development expertise

Globenewswire | 4 days ago
Outside Days Offer Intriguing Options Opportunity

Outside Days Offer Intriguing Options Opportunity

Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX).

Schaeffersresearch | 2 weeks ago
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

Paris,  May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal.

Globenewswire | 2 weeks ago

Biogen Inc. Dividends

Biogen Inc. logo
BIIB 2 Feb 2017
Paid
Other
$22.23 Per Share

Biogen Inc. Earnings

30 Jul 2025 (59 Days) Date
-
Cons. EPS
-
EPS
22 Apr 2025 Date
-
Cons. EPS
-
EPS
11 Feb 2025 Date
3.36
Cons. EPS
3.44
EPS
6 Nov 2024 Date
3.79
Cons. EPS
-
EPS
30 Oct 2024 Date
3.79
Cons. EPS
4.08
EPS
Biogen Inc. logo
BIIB 2 Feb 2017
Paid
Other
$22.23 Per Share
30 Jul 2025 (59 Days) Date
-
Cons. EPS
-
EPS
22 Apr 2025 Date
-
Cons. EPS
-
EPS
11 Feb 2025 Date
3.36
Cons. EPS
3.44
EPS
6 Nov 2024 Date
3.79
Cons. EPS
-
EPS
30 Oct 2024 Date
3.79
Cons. EPS
4.08
EPS

Biogen Inc. (BIIB) FAQ

What is the stock price today?

The current price is $129.79.

On which exchange is it traded?

Biogen Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is BIIB.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 18.43B.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Biogen Inc. ever had a stock split?

Biogen Inc. had 2 splits and the recent split was on Jan 18, 2001.

Biogen Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Christopher A. Viehbacher CEO
NASDAQ (NGS) Exchange
09062X103 Cusip
US Country
7,605 Employees
- Last Dividend
18 Jan 2001 Last Split
16 Sep 1991 IPO Date

Overview

Biogen Inc. is a pioneering biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. With a broad international presence, Biogen extends its reach across the United States, Europe, Germany, Asia, and other global regions. Since its founding in 1978, Biogen has been at the forefront of addressing some of the most challenging medical conditions, including multiple sclerosis (MS), spinal muscular atrophy, Alzheimer's disease, and psoriasis, among others. The company operates in collaboration with several notable industry partners, such as Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; and others, to advance its mission of transforming scientific discoveries into medical breakthroughs. Headquartered in Cambridge, Massachusetts, Biogen's commitment to improving patient care continues to drive its innovative research and drug development strategies.

Products and Services

Biogen's diverse portfolio showcases its dedication to treating complex neurological and neurodegenerative conditions:

  • TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA: These products are part of Biogen's multiple sclerosis (MS) treatment range, addressing various aspects of MS management to improve patient quality of life.
  • SPINRAZA: A groundbreaking therapy for spinal muscular atrophy, offering hope to individuals affected by this genetic disorder.
  • ADUHELM: Part of Biogen's Alzheimer's disease portfolio, this drug represents a significant advancement in treating a condition that affects millions of individuals worldwide.
  • FUMADERM: Developed for the treatment of plaque psoriasis, demonstrating Biogen's commitment to addressing autoimmune skin conditions.
  • Biosimilars (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ): These etanercept, adalimumab, infliximab, and ranibizumab biosimilars offer cost-effective alternatives to some of the most widely used biologic therapies for autoimmune diseases and macular degeneration.
  • RITUXAN (and RITUXAN HYCELA), GAZYVA, OCREVUS: Biogen's offerings in the oncology and MS spaces, including treatments for non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, and primary progressive MS, highlight the company's strong presence in developing therapies for both cancer and autoimmune diseases.
  • LUNSUMIO, glofitamab, and other anti-CD20 therapies: These therapies are designed for patients with relapsed or refractory follicular lymphoma and non-Hodgkin's lymphoma, showcasing Biogen’s ongoing dedication to innovative cancer treatment.

In addition, Biogen's pipeline includes a broad array of projects targeting MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, neuropsychiatry, genetic neurodevelopmental disorders, and the development of biosimilars. These initiatives, under various stages of development, signify Biogen's enduring commitment to expanding its impact on unmet medical needs and improving the lives of patients around the globe.

Contact Information

Address: 225 Binney Street
Phone: 617 679 2000